• Je něco špatně v tomto záznamu ?

Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial

G. Simonneau, AM. D'Armini, HA. Ghofrani, F. Grimminger, P. Jansa, NH. Kim, E. Mayer, T. Pulido, C. Wang, P. Colorado, A. Fritsch, C. Meier, S. Nikkho, MM. Hoeper,

. 2016 ; 4 (5) : 372-80. [pub] 20160408

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017311

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat. We also present safety and efficacy from the final data cutoff of CHEST-2, where most patients had received riociguat for at least 2 years. METHODS: Eligible patients from the CHEST-1 study entered the CHEST-2 open-label extension study, in which all patients received riociguat individually adjusted to a maximum dose of 2·5 mg three times per day. The primary endpoint was safety and tolerability. We did exploratory assessments of associations between markers of disease severity (6-min walking distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO functional class) at baseline and follow-up with overall survival and clinical worsening-free survival. We used Kaplan-Meier and Cox proportional hazards analyses. CHEST-2 is registered at ClinicalTrials.gov, number NCT00910429. FINDINGS: 237 patients entered CHEST-2. At 2 years, overall survival was 93% (95% CI 89-96) and clinical worsening-free survival was 82% (77-87). A significant association with overall survival was seen for 6MWD and NT-proBNP concentration at baseline (p=0·0199 and p=0·0183, respectively) and at follow-up (p=0·0385 and p=0·0068, respectively). Change from baseline in 6MWD was also significantly associated with survival (p=0·0047). WHO functional class at baseline and follow-up showed no significant association with overall survival but was associated with clinical worsening-free survival. Riociguat was well tolerated by most patients and no new safety signals were identified. Serious adverse events were seen in 129 (54%) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events. INTERPRETATION: Riociguat may be used long term in patients with CTEPH. 6MWD and NT-proBNP concentration are good prognostic markers. FUNDING: Bayer Pharma AG.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017311
003      
CZ-PrNML
005      
20180515103116.0
007      
ta
008      
180515s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2213-2600(16)30022-4 $2 doi
035    __
$a (PubMed)27067478
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Simonneau, Gérald $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France; INSERM Unité 999, l'Hopital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address: gerald.simonneau@abc.ap-hop-paris.fr.
245    10
$a Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial / $c G. Simonneau, AM. D'Armini, HA. Ghofrani, F. Grimminger, P. Jansa, NH. Kim, E. Mayer, T. Pulido, C. Wang, P. Colorado, A. Fritsch, C. Meier, S. Nikkho, MM. Hoeper,
520    9_
$a BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat. We also present safety and efficacy from the final data cutoff of CHEST-2, where most patients had received riociguat for at least 2 years. METHODS: Eligible patients from the CHEST-1 study entered the CHEST-2 open-label extension study, in which all patients received riociguat individually adjusted to a maximum dose of 2·5 mg three times per day. The primary endpoint was safety and tolerability. We did exploratory assessments of associations between markers of disease severity (6-min walking distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO functional class) at baseline and follow-up with overall survival and clinical worsening-free survival. We used Kaplan-Meier and Cox proportional hazards analyses. CHEST-2 is registered at ClinicalTrials.gov, number NCT00910429. FINDINGS: 237 patients entered CHEST-2. At 2 years, overall survival was 93% (95% CI 89-96) and clinical worsening-free survival was 82% (77-87). A significant association with overall survival was seen for 6MWD and NT-proBNP concentration at baseline (p=0·0199 and p=0·0183, respectively) and at follow-up (p=0·0385 and p=0·0068, respectively). Change from baseline in 6MWD was also significantly associated with survival (p=0·0047). WHO functional class at baseline and follow-up showed no significant association with overall survival but was associated with clinical worsening-free survival. Riociguat was well tolerated by most patients and no new safety signals were identified. Serious adverse events were seen in 129 (54%) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events. INTERPRETATION: Riociguat may be used long term in patients with CTEPH. 6MWD and NT-proBNP concentration are good prognostic markers. FUNDING: Bayer Pharma AG.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antihypertenziva $x aplikace a dávkování $7 D000959
650    _2
$a chronická nemoc $7 D002908
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x farmakoterapie $x etiologie $x mortalita $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a natriuretický peptid typu B $x krev $7 D020097
650    _2
$a plicní embolie $x komplikace $x farmakoterapie $x mortalita $7 D011655
650    _2
$a pyrazoly $x aplikace a dávkování $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $7 D011743
650    _2
$a čas $7 D013995
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a D'Armini, Andrea M $u Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, Italy.
700    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany; German Centre of Lung Research (DZL), Giessen, Germany; Department of Medicine, Imperial College London, London, UK.
700    1_
$a Grimminger, Friedrich $u University of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany; German Centre of Lung Research (DZL), Giessen, Germany.
700    1_
$a Jansa, Pavel $u Clinical Department of Cardiology and Angiology of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic.
700    1_
$a Kim, Nick H $u Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
700    1_
$a Mayer, Eckhard $u Kerckhoff Heart and Lung Centre, Bad Nauheim, Germany.
700    1_
$a Pulido, Tomas $u National Heart Institute, Cardiopulmonary Department, Mexico City, Mexico.
700    1_
$a Wang, Chen $u Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Beijing, China; Department of Respiratory Medicine, Capital Medical University, Beijing, China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, China.
700    1_
$a Colorado, Pablo $u Global Clinical Development, Bayer Pharma AG, Barcelona, Spain.
700    1_
$a Fritsch, Arno $u Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany.
700    1_
$a Meier, Christian $u Global Clinical Development, Bayer Pharma AG, Berlin, Germany.
700    1_
$a Nikkho, Sylvia $u Global Clinical Development, Bayer Pharma AG, Berlin, Germany.
700    1_
$a Hoeper, Marius M $u German Centre of Lung Research (DZL), Giessen, Germany; Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany.
773    0_
$w MED00188827 $t The Lancet. Respiratory medicine $x 2213-2619 $g Roč. 4, č. 5 (2016), s. 372-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27067478 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103250 $b ABA008
999    __
$a ok $b bmc $g 1300935 $s 1014151
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 4 $c 5 $d 372-80 $e 20160408 $i 2213-2619 $m The Lancet Respiratory medicine $n Lancet Respir Med $x MED00188827
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace